Investorideas.com
Search  Follow Investorideas on Twitter  Investorideas is on Facebook  Investorideas is on Google Plus  Investorideas is on Youtube  Investorideas is on Pinterest  Investorideas is on tumblr  Investorideas is on LinkedIn  Investorideas RSS 


Investorideas podcasts on iTunes, Google Play Music and iHeart.com

 


Investorideas Featured Company: Aethlon Medical (OTC:AEMDD)

Aethlon Medical, Inc.

News Archive

2015

2014

2013

2012

2011

Media Archive

2015

2014

2013

2012

2011

  • Our baby done growed up: Aethlon books first revenues ever on DARPA deal
    November 17, 2011
    By MassDevice staffAethlon Medical books its first revenues ever, on a payment from its $6.8 million contract with the Defense Advanced Research Projects Agency to develop its Adapt blood filtration system for treating service members with combat injuries.
  • Aethlon Medical receives $6.8M DARPA contract, Sand Diego Source - October 3, 2011
    By Daily Transcript staff report
  • Aethlon Medical Inc. (OTCBB: AEMD), a developer of therapeutic filtration devices, has been awarded a $6.8 million contract from the Defense Advanced Research Projects Agency (DARPA) to develop a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection that is often the cause of death in combat-injured soldiers.

    The contract program will utilize the Aethlon ADAPT system as a core technology component underlying an extracorporeal blood purification device that selectively clears multiple sepsis-enabling particles from circulation to promote recovery and prevent sepsis. The resulting device, which is being advanced under DARPA's Dialysis Like Therapeutics (DLT) program, is expected to dramatically decrease the morbidity and mortality of sepsis.

    Under the DLT program, Aethlon will also introduce a novel blood pump strategy to reduce or eliminate the systemic administration of anticoagulants normally required during extracorporeal device therapies. Worldwide, more than 18 million cases of sepsis are reported every year, with more than six million resulting in death.

    The Aethlon award from DARPA is a fixed-price. five-year contract valued at $6,794,389 with year one revenues of approximately $2 million.

  • Aethlon Medical, Inc. (OTCBB: AEMD) featured in Medical Design Online - September 21, 2011
  • San Diego Source - August 25, 2011
    Aethlon Medical Inc.: Company announced it has entered into an agreement with the Sarcoma Oncology Center to study the effectiveness of the Aethlon Hemopurifier to remove immunosuppressive exosomes from the blood of advanced-stage cancer patients.
  • Aethlon Medical Ramping Up Activities in 2011; Redcip.com blog
  • Aethlon Medical Announces Multi-Target Exosome Assay Validation - April 15, 2011

Disclaimer: Corporate Profile as prepared and approved by featured company.
* Investorideas.com disclaimer / disclosure

The following profile is a paid for submission/ad. Please read our full disclaimer and disclosure regarding specific compensation. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented.

BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894